Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid Data Could Support First-Line Use In Multiple Myeloma

This article was originally published in The Pink Sheet Daily

Executive Summary

Higher survival rate is seen with Revlimid in combination with lower-dose dexamethasone compared to use with a higher dose of the steroid.

You may also be interested in...



Velcade As Front-Line Multiple Myeloma Treatment Solidified By Phase III Data

Millennium plans to file an sNDA for the indication seeking a priority review by the first quarter of 2008.

Velcade As Front-Line Multiple Myeloma Treatment Solidified By Phase III Data

Millennium plans to file an sNDA for the indication seeking a priority review by the first quarter of 2008.

Celgene Counts On Apremilast To Expand Inflammatory Disease Pipeline

Second-quarter results spotlight 187 percent increase year-over-year in Revlimid revenues.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel